JP2013536243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536243A5 JP2013536243A5 JP2013526118A JP2013526118A JP2013536243A5 JP 2013536243 A5 JP2013536243 A5 JP 2013536243A5 JP 2013526118 A JP2013526118 A JP 2013526118A JP 2013526118 A JP2013526118 A JP 2013526118A JP 2013536243 A5 JP2013536243 A5 JP 2013536243A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- dimethyl
- amino
- amount
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 95
- 239000012453 solvate Substances 0.000 claims description 55
- -1 2-fluoro-4-iodo - phenylamino Chemical group 0.000 claims description 47
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 201000011510 cancer Diseases 0.000 claims description 47
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 35
- ZLOLCGXDJBXQCN-UHFFFAOYSA-N 5-[[4-[(2,3-dimethylindazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1CNC(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 ZLOLCGXDJBXQCN-UHFFFAOYSA-N 0.000 claims description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 29
- 206010006187 Breast cancer Diseases 0.000 claims description 26
- 208000026310 Breast neoplasm Diseases 0.000 claims description 26
- 206010033128 Ovarian cancer Diseases 0.000 claims description 26
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 26
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 26
- 206010060862 Prostate cancer Diseases 0.000 claims description 26
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 26
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 26
- 201000002528 pancreatic cancer Diseases 0.000 claims description 26
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 26
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 208000032839 leukemia Diseases 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims description 10
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 6
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 claims description 5
- 150000003462 sulfoxides Chemical class 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000012609 Cowden disease Diseases 0.000 claims description 4
- 201000002847 Cowden syndrome Diseases 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 4
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000000172 Medulloblastoma Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 206010047741 Vulval cancer Diseases 0.000 claims description 4
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 4
- 208000008383 Wilms tumor Diseases 0.000 claims description 4
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000008026 nephroblastoma Diseases 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 201000005102 vulva cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 3
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 2
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims 2
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 2
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 2
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 2
- 201000011143 bone giant cell tumor Diseases 0.000 claims 2
- 206010006007 bone sarcoma Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 66
- 238000001727 in vivo Methods 0.000 description 8
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 6
- ZLKZBUPPIMGGBF-UHFFFAOYSA-N Cl.CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O Chemical compound Cl.CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O ZLKZBUPPIMGGBF-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- JMYXMHBOFBYKDR-UHFFFAOYSA-N 2,3-dimethylindazole Chemical compound C1=CC=CC2=C(C)N(C)N=C21 JMYXMHBOFBYKDR-UHFFFAOYSA-N 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000007569 Giant Cell Tumors Diseases 0.000 description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 102000007530 Neurofibromin 1 Human genes 0.000 description 2
- 108010085793 Neurofibromin 1 Proteins 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000057028 SOS1 Human genes 0.000 description 2
- 108700022176 SOS1 Proteins 0.000 description 2
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 101150100839 Sos1 gene Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002768 hair cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- QOMRGRNKEDVKJV-UHFFFAOYSA-N 4-n-[(2,3-dimethylindazol-6-yl)methyl]-2-n-(4-methylphenyl)pyrimidine-2,4-diamine Chemical compound C1=CC2=C(C)N(C)N=C2C=C1CNC(N=1)=CC=NC=1NC1=CC=C(C)C=C1 QOMRGRNKEDVKJV-UHFFFAOYSA-N 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37719610P | 2010-08-26 | 2010-08-26 | |
| US61/377,196 | 2010-08-26 | ||
| PCT/US2011/048906 WO2012027438A1 (en) | 2010-08-26 | 2011-08-24 | Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536243A JP2013536243A (ja) | 2013-09-19 |
| JP2013536243A5 true JP2013536243A5 (enExample) | 2014-10-09 |
| JP5903433B2 JP5903433B2 (ja) | 2016-04-13 |
Family
ID=45723785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526118A Expired - Fee Related JP5903433B2 (ja) | 2010-08-26 | 2011-08-24 | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US20130165456A1 (enExample) |
| EP (1) | EP2608790A4 (enExample) |
| JP (1) | JP5903433B2 (enExample) |
| WO (1) | WO2012027438A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| WO2014085373A1 (en) * | 2012-11-27 | 2014-06-05 | Glaxosmithkline Llc | Combination |
| TWI839690B (zh) * | 2013-07-12 | 2024-04-21 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合的用途 |
| EP2913048A1 (en) * | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
| WO2018051306A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| KR20240032157A (ko) | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| US20230172936A1 (en) * | 2020-05-11 | 2023-06-08 | Cleave Therapeutics, Inc. | VCP/p97 INHIBITOR FOR THE TREATMENT OF CANCER |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE430742T1 (de) | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
| JP2007532658A (ja) | 2004-04-16 | 2007-11-15 | スミスクライン ビーチャム コーポレーション | がんの治療方法 |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| JP4163738B2 (ja) * | 2004-06-11 | 2008-10-08 | 日本たばこ産業株式会社 | 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物 |
| US20100130519A1 (en) * | 2007-04-13 | 2010-05-27 | Stephen Robert Wedge | Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii |
-
2011
- 2011-08-24 WO PCT/US2011/048906 patent/WO2012027438A1/en not_active Ceased
- 2011-08-24 US US13/819,091 patent/US20130165456A1/en not_active Abandoned
- 2011-08-24 EP EP11820572.3A patent/EP2608790A4/en not_active Withdrawn
- 2011-08-24 JP JP2013526118A patent/JP5903433B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-10 US US14/327,660 patent/US20140323506A1/en not_active Abandoned
-
2015
- 2015-08-19 US US14/829,689 patent/US20150352117A1/en not_active Abandoned
-
2017
- 2017-05-08 US US15/588,787 patent/US20170239255A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2290457T3 (es) | Tableta con alta carga de farmaco. | |
| JP2013536243A5 (enExample) | ||
| AU2022241561B2 (en) | Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase | |
| ES2329971T3 (es) | Composicion farmaceutica para la liberacion controlada de paracetamol. | |
| CN102781431B (zh) | 兽医组合物 | |
| JP2013541595A5 (enExample) | ||
| JP2017537899A5 (enExample) | ||
| ES2689685T3 (es) | Una composición farmacéutica estable que contiene amlodipina y valsartán | |
| JP2018168191A5 (enExample) | ||
| CN103945831A (zh) | 医药制剂 | |
| JP2015511635A (ja) | オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物 | |
| PT2305263E (pt) | Formas amorfas estabilizadas de mesilato de imatinib | |
| JP5903433B2 (ja) | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ | |
| AU2019232937B2 (en) | Ceritinib formulation | |
| ES2508490T3 (es) | Formulación de trimetazidina con diferentes perfiles de liberación | |
| RU2015117483A (ru) | Комбинации | |
| WO2012080703A1 (en) | Pharmaceutical composition comprising imatinib | |
| WO2013169218A1 (en) | Pharmaceutical compositions of s-etodolac | |
| JP2015503555A (ja) | ボセンタン制御放出性経口製剤 | |
| WO2018211336A2 (en) | Solid dosage form containing sorafenib tosylate | |
| JPWO2011081118A1 (ja) | 経口投与用医薬組成物 | |
| JP6858873B2 (ja) | セレコキシブを含む錠剤 | |
| ES2960207T3 (es) | Combinación de dosis fijas de liberación inmediata de memantina y donepezilo | |
| JP2013526613A5 (enExample) | ||
| WO2014139836A1 (en) | Pharmaceutical compositions comprising imatinib |